NCT06637007
Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Arms and interventions
1. Medication dosage:Chidamide Tablets(30mg,Twice a week,po),AK112(Once every 3 weeks). If you experience any discomfort during the medication process, please inform your responsible doctor in a timely manner. He/she will provide appropriate treatment based on the severity of the reaction. In severe cases, the dosage of medication will be adjusted until it is stopped. 2. Medication method: The interval between two oral doses of Xidabenzamide should not be less than 3 days (such as Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), and should be taken 30 minutes after breakfast. During the research process and before the end of medication, the responsible doctor will conduct physical and laboratory examinations on you in accordance with the experimental protocol to evaluate the impact of the experimental drug on you.
Drugs: Chidamide Tablets combined with AK112
Sites
1 site in 1 country
- Shanxi Cancer HospitalTaiyuan, Shanxi, China